Recto-Gluteal Fistula from Colonic Stent Migration and Perforation in a Patient with Metastatic Colorectal Cancer Treated with Folfox and Bevacizumab: A Case Report

Danielle Collins1* and Eric J Dozois2

1Department of Surgery, Mayo Clinic Rochester, USA
2Division of Colon & Rectal Surgery, Mayo Clinic Rochester, USA

*Corresponding author: Danielle Collins, Department of Surgery, Mayo Clinic Rochester, 200 First Street SW Rochester, MN 55905, USA, E-mail: daniellecol@gmail.com

Case Presentation

A 47-year-old female with metastatic colorectal cancer underwent colonic stenting for an obstructing lesion at the recto-sigmoid junction. Staging CT imaging demonstrated a large bowel obstruction due to a stricture lesion at the recto-sigmoid junction, numerous bilobar liver Mets and two lung nodules suspicious for metastatic disease. Colonoscopy and biopsy confirmed an adenocarcinoma 15 cm from the anal verge. She underwent an uneventful placement of a colonic self-expanding metal stent (SEMS) and then proceeded to undergo several cycles of systemic chemotherapy that included FOLFOX with bevacizumab. Three months later she developed severe pain in the right gluteal region and underwent a CT scan which demonstrated migration of the stent through the rectal wall, pelvic floor and gluteal musculature, creating a recto-gluteal fistula and abscess (Figure 1A and Figure 1B). She underwent incision and drainage of the gluteal abscess and formation of a transverse loop colostomy as an emergent procedure to control sepsis. One month later, she was referred to our institution for definitive surgical management. Following repeat imaging and multidisciplinary discussion with medical oncology, colorectal surgery and hepatobiliary surgery, a decision was made to perform an oncological colorectal resection with removal of the stent, reversal of the transverse loop colostomy, omental pedicle flap to the pelvis and construction of an end colostomy. The resected specimen (Figure 1C) showed a complete pathological response with negative lymph nodes (ypT0, N0).

Discussion

The addition of bevacizumab to chemotherapeutic regimens for metastatic colorectal cancer has shown improved survival [1]. There is however a recognized bowel perforation rate of 1.9% in patients undergoing this treatment [2]. Recently, there has been some concern that there is a higher risk of perforation in patients who have an endoluminal stent placed for obstruction at the time of treatment with bevacizumab [3]. Imbulgoda, et al. retrospectively reviewed 87 patients who underwent SEMS placement with an overall perforation rate of 10.3%. In this series, 2 out of 10 patients (20%) treated with bevacizumab had a perforation [4]. Small, et al. reported on stent complications in patients treated with bevacizumab (28 pts) and found a complication rate of 34.8%, including a perforation frequency of 17.4% [5]. Treatment with bevacizumab nearly tripled the risk of perforation in their overall cohort. The mechanism of perforation is yet to be elucidated but generally occurs within 21 days to 3 months of initiation of the anti-angiogenic therapy. It has been postulated that tumor growth and then shrinkage associated with inhibition of angiogenesis leads to impaired healing and perforation which may be compounded by the radial forces exerted from a self-expanding stent. Interestingly, bevacizumab impairs wound healing overall and the inability to mount an inflammatory fibrotic response may play a role in the
pathogenesis of a traumatic induced perforation. It is difficult to know exactly what the role of bevacizumab played in the complication from the stent in our patient. Given the perforation and dramatic migration of the stent, we strongly suspect that the combination of tumor regression, suppression of inflammatory response and delayed wound healing induced by bevacizumab is likely responsible.

Learning Point

This case highlights the potential for serious complications in bevacizumab treated colorectal cancer patients who have a colonic stent and the importance of early investigation of symptoms that may be secondary to a stent complication. Although stenting is useful in the emergent setting to relieve colonic obstruction, perhaps a diverting ostomy may be safer in the long-term for patients who will receive bevacizumab-based chemotherapy. Ultimately, a discussion with medical oncology may be beneficial in formulating a treatment plan prior to inserting a colonic stent.

Conflicts of Interest

The authors have no conflicts of interest or financial disclosures.

References


